
Carcinoma of the bladder, which is also known as transitional cell carcinoma, affects the urothelial cells that line the urinary tract- the bladder, the ureters, and a portion of the kidneys. Thus, it becomes the form most commonly associated with the bladder; however, it may also affect other urinary system structures.
Risk Factors:
The medical treatment of carcinoid tumours in India has adopted the newest research and technologies to meet worldwide clinical standards and healthcare capabilities.
The medical treatment for Urothelial Carcinoma requires evaluating the patient's severity and medical condition. The following are the treatment options:
Transurethral Resection of Bladder Tumor (TURBT): minimally invasive surgery for surgically removing superficial tumours from the bladder.
Chemotherapy : It is intravesical for superficial tumours, while systemic (e.g., Gemcitabine and cisplatin) for tumours that have grown into muscle or metastasised.
Cost Start From USD 600 - USD 700Explore Options
Immunotherapy : Checkpoint inhibitors stimulate the immune system to attack cancer cells and are used mainly in advanced or resistant cases to chemotherapy.
Cost Start From USD 3000 - USD 5000Explore Options
Radiation Therapy: Advanced palliative care based on external beam radiation can involve using this radiation either alone or following surgery. The advanced disease can also be treated because symptoms such as bleeding and obstruction require palliative care.
Targeted Therapy and BCG: Targeted medications that aim at specific genetic mutations. However, BCG activates the immune system against non-muscle-invasive bladder cancer, improving outcomes.
Cost Start From USD 8000 - USD 12000Explore Options
These are the standard diagnostic methods for diagnosing Urothelial Carcinoma:
MediRehab (chain of Rehab centres - part of MediGence provides comprehensive rehabilitation services designed to support patients in India. Additional services are as per the patient's requirement. These services include:









Delhi, India
Clear Medi Hospital, Karkardooma located in New Delhi, India is accredited by ISO. Also listed below are some of the most prominent infrastructural details:

Hyderabad, India
American Oncology Institute located in Hyderabad, India is accredited by AAAHC. Also listed below are some of the most prominent infrastructural details:

Chennai, India
MIOT started its journey with only 70 beds and focusing on Orthopedics and Trauma care. However, we grew into a multi-specialty hospital with time. MIOT is now a 1000-bedded hospital and can offer an extensive range of services across 63 specialties. The state of art laboratory of our hospital is ranked 8th internationally. We have 21 super-specialty operation theaters equipped with cutting-edge technology to help our doctors with complex procedures.
We take great care to make our patient rooms comfortable enough. The patient rooms get plenty of fresh air as well as natural light. The soothing views from the rooms do not let the patients feel cut off from the outside world. We use separate entrances for emergency patients, out-patients, in-patients, and their attendants. We put our patients’ safety first which is why we use a superior air system to ensure a near-zero infection healthy environment.
Apart from that, MIOT’s 24 hours blood bank provides all kinds of blood work related services which include blood collection to component separation. This state-of-art blood bank alone handles more than 30,000 units of blood over the course of a year. Every month around 600 blood transfusions are managed by this blood bank.
MIOT’s SIGNA Pioneer 3T MRI machine is made with noise reduction technology. This silent MRI machine can deliver superior quality neuroimages without wasting any time. The department of Radiology and Imaging Sciences can give tough competition to any international hospital with its advanced technology and accuracy.
The PET CT service at MIOT International is the first of its kind in South India enabling better and more accurate diagnosis than earlier. The superior diagnosis is also possible for the two digital cath labs at MIOT Heart Revive center.
We also have a physiotherapy team where a team of highly efficient physiotherapists deals with the mobility and functional disability issues of our patients. They listen to the patients carefully to identify the root of the pain and use therapeutic exercises to reduce their pain.
The CCU of MIOT is something to be proud of. The specially-trained staff of this unit is dedicated to ensuring top-quality medical support to serious patients. This unit along with the MIOT International Laboratory is the backbone of our facility.
Furthermore, what makes MIOT unique is our Telemedicine service. In the new normal, we are trying everything to reach our patients. Our one of its kind Telemedicine service connects our patients to our 250 full-time doctors over email, phone, chat and video consultations.
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
The following are the much-growing reasons for India being frequented for Urothelial Carcinoma treatment:
Although one cannot prevent the disease, risk factor reduction- for example, quitting smoking, eating good food, staying hydrated, and avoiding chemicals can reduce the possibility of urothelial carcinoma development.
The prognosis is determined by the stage at which the cancer was diagnosed. Late-stage tumours are considered aggressive and associated with a poor prognosis, while early-stage non-muscle-invasive bladder cancer is associated with a reasonable survival rate.
PCPs and immune checkpoint inhibitors support a patient's immune system in recognising and destroying cancer cells in advanced or metastatic urothelial carcinoma cases.
Yes, urothelial carcinoma can recur, particularly in the setting of non-muscle invasive cancers. Follow-up through cystoscopies and urine tests can help detect recurrences as early as possible.
The side effects may change from treatment to treatment. They include fatigue, nausea, hair loss, urinary problems, infections, and immune-mediated side effects (in the case of immunotherapy). Managing side effects is the most critical part of the treatment journey.
Bladder cancer, specifically urothelial carcinoma, is relatively common in India, and there is an increasing incidence mainly because of clearly defined risk factors such as smoking and exposure to environmental toxins. It's among the commonly recorded malignancies of the urinary tract in India.
The probability of survival of patients with urothelial carcinoma correlates with the stage of cancer at diagnosis. Early recognition significantly augments the chances of survival, especially concerning non-muscle invasive bladder cancer. At the same time, advanced stages may confer a lesser survival probability because of being detected late and getting access to advanced treatment facilities in some regions.
In India, it is more common in men than in women. Men aged 50 years and above, especially those with a history of smoking and occupational exposure to chemicals, are at greater risk. However, bladder cancer in women is also on the rise.
Treatment is usually stage-dependent but may vary somewhat based on tumour location. Surgery, chemotherapy, immunotherapy, and sometimes radiation are often used in combinations. These combinations may enhance response to treatment, particularly amongst the advanced cases.